Cytosorbents (CTSO) EBITDA Margin Growth (5y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Cytosorbents | 28.81 Mn | 24.01 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -743.00 |
| Dec 31, 2025 | -2,545.00 |
| Sep 30, 2025 | -1,159.00 |
| Jun 30, 2025 | -392.00 |
| Mar 31, 2025 | -1,190.00 |
| Dec 31, 2024 | 2,454.00 |
| Sep 30, 2024 | 4,357.00 |
| Jun 30, 2024 | 2,055.00 |
| Mar 31, 2024 | 3,637.00 |
| Dec 31, 2023 | -2,327.00 |
| Sep 30, 2023 | -3,283.00 |
| Jun 30, 2023 | 2,002.00 |
| Mar 31, 2023 | -1,626.00 |
| Dec 31, 2022 | 515.00 |
| Sep 30, 2022 | -5,013.00 |
| Jun 30, 2022 | -3,261.00 |
| Mar 31, 2022 | -3,644.00 |
| Dec 31, 2021 | 5,498.00 |
| Sep 30, 2021 | 3,786.00 |
| Jun 30, 2021 | 8,776.00 |
| Mar 31, 2021 | 8,809.00 |
| Dec 31, 2020 | 16,016.00 |
| Sep 30, 2020 | 19,705.00 |
| Jun 30, 2020 | -17,454.00 |
| Mar 31, 2020 | 57,210.00 |
| Dec 31, 2019 | 49,168.00 |
| Sep 30, 2019 | 1,911.00 |
| Jun 30, 2019 | 11,955.00 |
| Mar 31, 2019 | 355.00 |
| Dec 31, 2018 | -4,614.00 |
| Sep 30, 2018 | 8,596.00 |
| Jun 30, 2018 | 101,676.00 |
| Mar 31, 2018 | 85,913.00 |
| Dec 31, 2017 | 55,276.00 |
| Sep 30, 2017 | 470,524.00 |
| Jun 30, 2017 | 202,887.00 |
| Mar 31, 2017 | 278,715.00 |
| Dec 31, 2016 | 254,061.00 |